ERA-EDTA Congress 2011: Late Breaking Clinical Trials II
PRAGUE, June 25, 2011 /PRNewswire/ –
The SHARP-study has shown that lowering LDL cholesterol with
ezetimibe/simvastatinleads to a significant reduction in major
atherosclerotic events among CKD-patients. Whether it also has a favourable
effect on renal disease progression was another of the issues addressed by
the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group,
fewer patients reached the end point “end stage renal disease”, but the
difference was not significant [p = 0.41].
No improvement in cardiovascular outcome due to optimised treatment
Cardiovascular comorbidity in CKD patients is dramatically high. The
MASTERPLAN study [abstract no. 2511] aimed to evaluate whether strict
implementation of all the current treatment guidelines leads to a better
cardiovascular outcome in CKD patients. The primary endpoint was a composite
of myocardial infarction, stroke and cardiovascular death. Despite
intensified therapy and better lab values it was not possible to
significantly improve cardiovascular outcome in the intervention group.
Benefits of tacrolimus therapy with prolonged release in de novo kidney
Various immunosuppressive drugs are available, one of these being
tacrolimus (Tac). There are tacrolimus products that release their active
substance immediately (Tac BID) and others that release it in a prolonged
manner (Tac QD). The open-label OSAKA study [abstract no. 2505] compared
these two drug forms in various doses. Tac QD led to the achievement of
target blood level in more patients within the first few days after
transplantation than Tac BID in an identical dose.
Which SHPT therapy should be used?
In the randomised phase IV IMPACT study [abstract no. 2519] 272
hemodialyis patients with seconday hyperparathyreoidism received either
paricalcitol or cinacalcet plus low-dose vitamin D. This interim analysis
showed that in the paricalcitol group 78% of patients achieved an iPTH
reduction of =30% and 65% achieved a reduction of =50% whilst in the
cinacalcet group the figures were 50% and 36% of patients. Concerning side
effects, 4 of 69 patients developed hypercalcaemia in the paricalcitol arm,
while 27 of 59 patients developed hypocalcemia in the cinacalcet arm.
For further information http://www.eraedta2011.org/press.html Bettina Albers email@example.com +49(0)174-2165629
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDT